Patients with a diagnosis of acute deep venous thrombosis have traditionally been hospitalized and treated with unfractionated heparin followed by oral anticoagulation therapy. Several clinical trials have shown that low-molecular-weight heparin is at least as safe and effective as unfractionated heparin in the treatment of uncomplicated deep venous thrombosis. The use of low-molecular-weight h...

BACKGROUND Acute lung injury (ALI) is characterized by a pro-coagulant state. Heparin is an anticoagulant with anti-inflammatory properties. Unfractionated heparin has been found to be protective in experimental models of ALI. We hypothesized that an intravenous therapeutic dose of unfractionated heparin would favorably influence outcome of critically ill patients diagnosed with ALI. METHODS ...

Heparin-induced thrombocytopenia (HIT) is an immune-mediated adverse drug effect from unfractionated or low-molecular weight heparin that results in and potentially catastrophic thrombosis. HIT occurs due to the development of platelet-activating antibodies against multimolecular complexes platelet factor 4 (PF4) heparin. Given frequency use among hospitalized patients, calculation 4Ts Score re...

For many years unfractionated heparin (UFH) was the only antithrombotic agent available in the United States. However, during the past decade new antithrombotic agents have become available. Th e fi rst of these agents were the low-molecular weight heparins (LMWHs) followed more recently by the direct anti-Xa inhibitors, of which only fondaparinux is available in the United States. Low-molecula...

Unfractionated heparin and low-molecular-weight heparins are commonly used as thromboprophylaxis for hospitalized patients. Though generally considered safe at prophylactic doses, cases of catastrophic hemorrhage have been reported. The proposed mechanism involves bioaccumulation of heparin through saturation of the rapid-elimination pathway in its metabolism. We present an unusual case of an a...

Neurosurgical patients are at great risk for venous thromboembolism. Thromboprophylaxis is either with unfractionated heparin or low molecular weight heparin (LMWH). In neurosurgery, this is a matter of debate because of fear from bleeding. Few randomized studies show that chemical prophylaxis is safe after elective neurosurgeries. Prophylaxis with gradual elastic stocking and venous pump may b...

BACKGROUND Low molecular weight heparins hold several advantages over unfractionated heparin including convenience of administration. Enoxaparin is one such heparin licensed in the UK for use in unstable coronary artery disease (unstable stable angina and non-Q wave myocardial infarction). In these patients, two large randomised controlled trials and their meta-analysis showed small benefits fo...

A dynamic mixture of iron complexes was used as a colorimetric sensor for sulfated glycosaminoglycans. The sensing ensemble was prepared by mixing [FeCl(2)(H(2)O)(4)] with dipicolylamine, the functionalized bipyridyl ligand N-(6-aminohexyl)-4'-methyl-2,2'-bipyridine-4-carboxamide, and the dye Evans Blue. Upon addition of the analytes, characteristic changes in the UV-Vis spectrum of the solutio...

OBJECTIVE To compare the safety and efficacy of enoxaparin and unfractionated heparin in the treatment of submassive pulmonary thromboembolism (PTE). MATERIAL AND METHODS Fifty-six patients with PTE who did not need fibrinolytic treatment were enrolled prospectively. The patients were randomly assigned to 2 treatment groups: Group A received enoxaparin (1 mg/kg every 12 hours) and Group B rec...